Coremed, Inc. is a privately funded biotech company founded in 1994. Coremed has developed an inhalable form of insulin based on a proprietary new platform for drug delivery. Our first product "Alveair", boasts close to 100% bio-availability, no respiratory side-effects during preliminary human trials, and oral delivery rendering injections unnecessary. Alveair has generated tremendous interest from major pharmaceutical companies and trade organizations, and is currently beginning Phase 1 clinical trials.